Announced
Completed
Financials
Tags
oncology therapeutics
Biotechnology
Domestic
Majority
United States
Acquisition
Merger
Private
Friendly
Completed
Single Bidder
Synopsis
Immunome, a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system, completed the merger with Morphimmune, a biotechnology company focused on developing targeted oncology therapeutics, in a $125m deal. “This merger is an essential step in establishing a preeminent oncology company. We believe that we are well positioned to advance our current oncology pipeline into the clinic, build upon the pipeline through our technology platform and proprietary toolbox, and expand our portfolio through strategic transactions focused on clinical and preclinical assets,” Clay Siegall, Morphimmune President and CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.